Liquidia Says Court Denies United Therapeutics' Motion For Injunction To Block Launch Of YUTREPIA
(RTTNews) - Liquidia Corp. (LQDA) announced Monday that Judge Andrews of the U.S. District Court for the District of Delaware (District Court) denied the motion for preliminary injunction filed by United Therapeutics (UTHR) on Friday that sought to block the launch of Liquidia's YUTREPIA (treprostinil) inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The ruling reinforces the clear path for the U.S. Food and Drug Administration (FDA) to issue a final decision on the amended New Drug Application (NDA) for YUTREPIA.
The motion for preliminary injunction was filed in the lawsuit filed by United Therapeutics in September 2023 in which it has alleged YUTREPIA would infringe U.S. Patent No. 11,826,32.
While this ruling maintains the status quo in which there is no legal impediment to the FDA granting final approval to YUTREPIA, this lawsuit will continue forward to trial, which is currently scheduled for June 2025.
Separately, United Therapeutics has also appealed Judge Andrews' ruling to set aside an injunction that he had previously issued blocking the launch of YUTREPIA based solely on the '793 Patent.
Liquidia CFO Michael Kaseta Takes On Additional Role Of COO
U.S. Jobless Claims Unexpectedly Dip From Upwardly Revised Level
Canadian Stocks Poised For Weak Open As Oil Surges On Iran Tensions
U.S. Weekly Jobless Claims Unexpectedly Dip To 197,000
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
FTSE 100 Recovers From Early Lows, Down Just Marginally
AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO - Update
